Prediction of clinical risk assessment and survival in chronic obstructive pulmonary disease with pulmonary hypertension

Dansha Zhou; Chunli Liu; Lan Wang; JiFeng Li; Yating Zhao; Zheng Deng; Chi Hou; Yingyun Fu; Qian Jiang; Ning Lai; Rui Zhang; Weici Feng; Chuhui Gao; Xiang Li; Mei Jiang; Xin Fu; Jiyuan Chen; Wei Hong; Lei Xu; Wenjun He; Jinming Liu; YuanHua Yang; Wenju Lu; Nanshan Zhong; Yunshan Cao; Jian Wang; Yuqin Chen

doi:10.1002/ctm2.1702

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (6) : e1702 DOI: 10.1002/ctm2.1702

RESEARCH ARTICLE

Prediction of clinical risk assessment and survival in chronic obstructive pulmonary disease with pulmonary hypertension

Author information +

¹. State Key Laboratory of Respiratory Diseases, National Center for Respiratory Medicine, Guangdong Key Laboratory of Vascular Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

². Department of Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China

³. Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

⁴. Department of Cardiology, Gansu Provincial Hospital, Lanzhou, Gansu, China

⁵. The First People's Hospital of Yunnan, Kunming, Yunnan, China

⁶. Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China

⁷. Department of Pulmonary and Critical Care Medicine, Shenzhen Institute of Respiratory Disease, Shenzhen Institute of Respiratory Disease,Shenzhen People's Hospital ( The Second Clinical Medical College，Jinan University；The First Affiliated Hospital, Southern University of Science and Technology）, Shenzhen, Guangdong, China

⁸. GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, Guangdong, China

⁹. Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia Autonomous Region, Hohhot, China

¹⁰. Heart, Lung and Vessels Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China

¹¹. Guangzhou Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, China

¹². Section of Physiology, Division of Pulmonary, Critical Care and Sleep Medicine, University of California, San Diego, La Jolla, California, USA

yunshancao@126.com

jianwang@gzhmu.edu.cn

yqchen@gzhmu.edu.cn

Show less

History +

PDF

Abstract

• A multicentre study with a large sample of chronic obstructive pulmonary disease (COPD) patients diagnosed with PH through right heart catheterisation.

• A non-invasive online clinical tool for assessing severe pulmonary hypertension (PH) in COPD.

• The first risk assessment tool was established for Chinese patients with COPD– PH.

Keywords

COPD / nomogram / pulmonary hypertension / survival

Cite this article

Download citation ▾

Dansha Zhou,Chunli Liu,Lan Wang,JiFeng Li,Yating Zhao,Zheng Deng,Chi Hou,Yingyun Fu,Qian Jiang,Ning Lai,Rui Zhang,Weici Feng,Chuhui Gao,Xiang Li,Mei Jiang,Xin Fu,Jiyuan Chen,Wei Hong,Lei Xu,Wenjun He,Jinming Liu,YuanHua Yang,Wenju Lu,Nanshan Zhong,Yunshan Cao,Jian Wang,Yuqin Chen. Prediction of clinical risk assessment and survival in chronic obstructive pulmonary disease with pulmonary hypertension. Clinical and Translational Medicine, 2024, 14(6): e1702 DOI:10.1002/ctm2.1702

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (Lond Engl). 2018;392(10159):1736-1788.

[2]	BuistAS, McBurnie MA, VollmerWM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet (Lond Engl). 2007;370(9589):741-750.

[3]	LozanoR, Naghavi M, ForemanK, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (Lond Engl). 2012;380(9859):2095-2128.

[4]	Mueller-MottetS, Stricker H, DomenighettiG, et al. Long-term data from the Swiss pulmonary hypertension registry. Respiration. 2015;89(2):127-140.

[5]	MinaiOA, Chaouat A, AdnotS. Pulmonary hypertension in COPD: epidemiology, significance, and management pulmonary vascular disease: the global perspective. Chest. 2010;137(6):39s-51s.

[6]	AndersenKH, Iversen M, KjaergaardJ, et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant. 2012;31(4):373-380.

[7]	BunelV, GuyardA, DauriatG, et al. Pulmonary arterial histologic lesions in patients with COPD with severe pulmonary hypertension. Chest. 2019;156(1):33-44.

[8]	HumbertM, KovacsG, HoeperMM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879.

[9]	GalièN, Torbicki A, BarstR, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25(24):2243-2278.

[10]	DeañoRC, Glassner-Kolmin C, RubenfireM, et al. Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. JAMA Intern Med. 2013;173(10):887-893.

[11]	HumbertM, KovacsG, HoeperMM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731.

[12]	RileyCM, Sciurba FC. Diagnosis and outpatient management of chronic obstructive pulmonary disease: a review. JAMA. 2019;321(8):786-797.

[13]	HeagertyPJ, LumleyT, PepeMS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337-344.

[14]	GailMH, Pfeiffer RM, CaiT. Six articles related to risk assessment and prediction based on work presented at the October 12–14, 2011 conference on risk assessment and evaluation of predictions in Silver Spring, Maryland. Lifetime Data Anal. 2013;19(2):139-141.

[15]	SteyerbergEW, Vickers AJ, CookNR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128-138.

[16]	KerrKF, BrownMD, ZhuK, JanesH. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol. 2016;34(21):2534-2540.

[17]	RileyRD, EnsorJ, SnellKIE, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441.

[18]	KovacsG, AvianA, BachmaierG, et al. Severe pulmonary hypertension in COPD: impact on survival and diagnostic approach. Chest. 2022;162(1):202-212.

[19]	BalasubramanianA, Kolb TM, DamicoRL, HassounPM, McCormack MC, MathaiSC. Diffusing capacity is an independent predictor of outcomes in pulmonary hypertension associated with COPD. Chest. 2020;158(2):722-734.

[20]	ChaouatA, NaeijeR, WeitzenblumE. Pulmonary hypertension in COPD. Eur Respir J. 2008;32(5):1371-1385.

[21]	NakaharaY, Taniguchi H, KimuraT, et al. Exercise hypoxaemia as a predictor of pulmonary hypertension in COPD patients without severe resting hypoxaemia. Respirology (Carlton Vic). 2017;22(1):120-125.

[22]	BarberàJA, Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs. 2009;69(9):1153-1171.

[23]	JiangR, WangL, ZhaoQH, et al. Echocardiography nomogram for predicting survival among chronic lung disease patients with severe pulmonary hypertension. J Clin Med. 2022;11(6):1603.

[24]	LiY, ZhangR, ShanH, et al. FVC/D(LCO) identifies pulmonary hypertension and predicts 5-year all-cause mortality in patients with COPD. Eur J Med Res. 2023;28(1):174.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.